Table 2.
REEP1 mutations and clinical characteristics
| Family | ANT25 | ANT28 | ANT40 | BO1-0009 | BO1-0010 | TU2-0077 | 03-0914 | 02-1764 | 05-3263 | M1516 | I1018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mutation | c.-1_2delCAT | c.595G>C | c.104_105delAT | c.606 + 43G>T; miR140 | c.183-1 _183insCT | c.303G>A | c.282delC | c.417 + 1G>T | c.417 + 1G>T | c.537_540delCGGC | c.33-?_606+ ?dup |
| No of individuals genotyped (affected) | 9(2) | 3(2) | 8(5) | 2(1) | 2(2) | 1(1) | 1(1) | 2(2) | 2(2) | 39(21) | 1(1) |
| No of individuals clinically examined | 3 | 2 | 3 | 1 | 2 | 1 | 1 | 2 | 3 | 14 | 2 |
| Origin | Belgium | Belgium | Spain | Germany | Germany | Germany | The Netherlands | The Netherlands | The Netherlands | The Netherlands | Ireland |
| Mode of inheritance | AD | AD | AD | AD | AD | S | S | AD | AD | AD | AD |
| Phenotype | Pure | Pure | Pure | Pure | Pure | Pure | Pure | Pure | Pure | Pure | Pure |
| age at onset in years | 4; 32a | 4; 5 | <10 (3x) | 50c | 3; 3 | 42 | <10 | 2; 38 | 8; 11; 14 | range 1–75 | 42; 90 |
| Mean disease duration in years [range] | 18 [17–19] | 16.5 [3–30] | 2–5 decades/unknown | 9 | 21 | 12 | > 4 decades | unknown | 25 [19–31] | 0.5–1 | 5 |
| Severity | Mild– moderate | Mild–moderate | Mild– moderate | Mild | Mild | Mild | Severe | Mild | Moderate – severe | Mild–moderate – severe | Mild–moderate |
| Lower limb spasticity | + | + | + | + | + | + | + | + | + | + | + |
| Lower limb weakness | Distal | Variable | − | + | + | + | ++ | Distal | Variable | Variable | + |
| Muscle wasting | − | Variable | − | − | + | Distal | − | − | Variably distal | Variable | |
| Hyperreflexia | + | + | + | + | + | + | − | + | + | + | |
| Plantar reflexes | Extensor | Extensor | Variably extensor | Extensor | Extensor | Extensor | Extensor | Extensor | Variably extensor | Extensor | Extensor |
| Vibration sense (ankles) | Normal | Variably decreased | Normal | Decreased | Normal | Normal | Decreased | Variably decreased | Variably decreased | Normal | Decreased |
| Bladder disturbances | − | Variably urgency | − | Urgency | − | − | − | − | Urgency | − | Urgency |
| Additional features | − | Distal amyotrophy of upper limbs, scoliosisb | − | − | − | − | − | − | − | Muscle weakness of handsb | Early upper limb involvement |
| MRI | Normal (III.2: right cerebellar venous angioma) | II.1: small unspecific white matter lesions in frontal lobe | III.1 normal | n.d. | n.d. | white matter lesion above the trigonum | n.d. | normal | CCT normal | normal | normal |
| Neurophysiology | IV.1: normal | II.1: sensory-motor per- ipheral neuropathy in upper limbs | III.1 normal | No MEP; NCV normal | MEP normal, NCV normal | CMT increased latency; NCV normal | n.d. | n.d. | normal | n.d. | n.d. |
n.d. = not determined; No MEP = no motor-evoked potential after cortical stimulation; CMT = central motor conduction time; NCV = nerve conduction velocity; AD = autosomal dominant; S = sporadic; CCT = cranial computer tomography.
One mutation carrier (ANT 25-II.2 in Fig. 2) did not show any signs of spasticity upon examination at age 76.
Additional features only found in older affected.
Sibbling of index patient (BO1-0009-II.2 in Fig. 2) is subjectively asymptomatic at age 56 but has not consented to a neurological examination.